|
Abstract
|
Neuroinflammation and neurotrophic factors including brain derived neurotrophic factor (BDNF) and neurotrophin 3 (NT3) are implicated in the pathophysiology of autism spectrum disorder (ASD). S100B, a protein released from astrocytes, reflects the neuroinflammation and increases in ASD. The aim of this study was to examine the interventions on the serum levels of S100B in relation to NT3 and BDNF in patients with first diagnosed ASD group (untreated, n=28) in comparison with the patients with ASD who had previous history of interventions (treated, ASD+I, group n= 24) in the range of 32-37 months. Also, it has been enrolled 29 healthy children (n=29) in the range of 25-65 months as control group. S100B level was found to be higher in patients with ASD than control and I+ASD groups. Interventions reversed the higher S100B level to control values. NT3 level increased significantly in ASD+I group when compared to ASD and control values. Although, BDNF levels were not different between groups, a significant positive correlation between NT3 and BDNF was found in ASD+I group. Interventions seem to appear to abolish the increased level of S100B and produce alterations in BDNF and NT3 in patients with ASD.
|
